1	Meta-analysis of COVID-19 patients to understand the key predictors of mortality
2	in the non-vaccinated groups in remote settings
3	
4	
5	Authors
6	Neha L. Jain MD, ¹ Karishma Parekh MD ^{1,3} , Rishi Saigal MD ¹ , Amal Alyusuf MD ¹
7	Gabrielle Kelly MD ¹ , Alokkumar Jha PhD ^{4,5,6,7}
8	
9	¹ CHI Mercy health, Roseburg, Oregon, USA
10	³ Sutter Gould Medical Foundation, CA, USA
11	⁴ Cardiovascular Institute, Stanford University School of Medicine, Stanford University,
12	CA, USA
13	⁵ Division of Pediatric Endocrinology and Diabetes, Stanford University, CA, USA
14	⁶ Stanford Cancer Institute, Stanford University, CA, USA
15	⁷ Centre for Neurogenetics, Weill Cornell Medicine, New York, USA
16	
17	
18	Keywords: Rural Health, SARS-COV2, Vaccination, Cytokine storm
19	
20	Word count: (8807 words)
21	
22	
23	
24	
25	
26	

Abstract: Various studies have looked into the impact of the COVID-19 vaccine on large 27 populations. However, very few studies have looked into the remote setting of hospitals 28 where vaccination is challenging due to social structure, myths, and misconceptions. There 29 is a consensus that elevated inflammatory markers such as CRP, ferritin, D-dimer correlate 30 with increased severity of COVID-19 and are associated with worse outcomes. In the 31 present study, through retrospective meta-analysis, we have looked into ~20 months of 32 33 SARS-COV2 infected patients with known mortality status and identified predictors of mortality concerning their comorbidities, various clinical parameters, inflammatory 34 markers, superimposed infections, length of hospitalization, length of mechanical 35 ventilation and ICU stay. Studies with larger sample sizes have covered the outcomes 36 through epidemiological, social, and survey-based analysis—however, most studies cover 37 larger cohorts from tertiary medical centers. In the present study, we assessed the outcome 38 of non-vaccinated COVID 19 patients in a remote setting for 20 months from January 1, 39 2020, to August 30, 2021, at CHI Mercy Health in Roseburg, Oregon. We also included 40 two vaccinated patients from September 2021 to add to the power of our cohort. The study 41 will provide a comprehensive methodology and deep insight into multi-dimensional data 42 in the unvaccinated group, translational biomarkers of mortality, and state-of-art to conduct 43 such studies in various remote hospitals. 44

45

46 Introduction

The disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), known as coronavirus disease 2019 (COVID-19), has been classified as a pandemic by the World Health Organization (WHO) by February 2020. As of today, over ~28.7 million cases have been reported worldwide, with more than ~5.1 million deaths¹. The effects of the pandemic have been incredibly profound in the unvaccinated group, and a majority of them are destined to comprise the high-risk group of patients². The likelihood of their increased severity is induced by but not limited to advanced age, underlying comorbidities,

and compromised immune status. The aforementioned comorbidities can have similar 54 gravitas of disease impact in the vaccinated group; however, the mortality rate is much 55 lower than earlier. One of the proposed mechanisms for increased severity is endothelial 56 dysfunction, most commonly seen in these chronic illnesses and is exacerbated in COVID-57 19 infection. It is associated with increased complications such as Acute respiratory distress 58 syndrome (ARDS), coagulation imbalance, cytokine storm, and multiorgan failure³. It 59 60 remains elusive if there is a host hyperimmune reaction or host immune dysfunction when infected with SARS-CoV-2, resulting in multi-organ dysfunction. Cytokine storm-related 61 to COVID-19 is associated with poor outcomes. Various cytokine levels such as 62 interleukin-1β, interleukin-6, TNF, and many more are noted to be elevated. It is unclear if 63 the cytokine storm drives COVID-19 infection or is a secondary process.⁴ 64

As discussed earlier, a plethora of studies have indicated a relatively high risk of severe 65 COVID-19 in the unvaccinated group of patients⁴; however, the studies have failed to 66 capture its impact in remote locations and corresponding medical centers with low 67 vaccination rates, which favors the rapid spread of the virus, posing a health risk for all the 68 individuals within the community. Further, most studies in this area have been either 69 behavioral or observational rather than clinical and retrospective to explain the conditions 70 and microenvironment due to remote location challenges. Additionally, previous 71 publications of outcomes for the unvaccinated cohort repeatedly demonstrated relatively 72 high mortality for the subgroup of patients without vaccination. 73

Given the general paucity of information regarding factors associated with severe COVID-19 in patients without vaccination, relatively high-level information regarding the outcomes of patients in remote settings would be of high interest to the community of remote medical centers in guiding management decisions. In this vein, we have decided to conduct this unique study by performing a descriptive meta-analysis in a remote hospital situated in Roseburg, Oregon. The primary purpose of the current research is to develop a formal statistical model to compare the independent associations of any differences in

descriptive and clinical data with fatal COVID-19 outcomes stratified based on the
vaccination status. Having such a study conducted in a remote setting hospital will be a
beacon of hope for other similar studies and observations in other remote hospitals within
the United States and around the world.

To achieve this, we have developed a mathematical model to identify the severity and predictors of mortality in unvaccinated COVID-19 patients trading off clinical variables such mechanical ventilation duration, severe illness requiring admission to a hospital, requirement of ICU level of care, and laboratory values. The primary focus was to build independent associations of outcome/mortality with state of disease, line of therapy received, and recent use of immunosuppressant therapy.

91

92 Background

93

Most studies on COVID-19 so far have focused on urban centers resulting in a paucity of 94 data on how the current pandemic has affected the rural population and medical centers in 95 the US and across. More diverse studies pertaining to localized information in remote 96 hospitals needed for COVID-19 infection related biomarkers, 97 are to treatments/management, and interventions and their outcomes. To captivate that, we have 98 conducted a study at CHI Mercy Health, a private, not-for-profit 174-bed rural medical 99 center located in Roseburg, Oregon. It has a population of 23,479, of which 22.3% are 100 persons of age 65 and over. About 12.7% of the population live in poverty, with 22.9% on 101 Medicaid and 14.1% on Medicare. The socio-economic conundrum made the COVID-19 102 impact worse in the area owing to various factors like lack of infrastructure, early treatment 103 unavailability, and failure in convincing local people to get vaccinated. As of October 29th, 104 2021, the state epidemiological data suggested that only 49% of Douglas county's 105 population has been vaccinated. Low rate of vaccination added a lot more to the emotional, 106 social, and personalized health burden on the medical fraternity by in-patient 107

hospitalization flow due to low vaccination rate, which led the resources under severe 108 109 strain⁵. Various studies also looked into the retrospective data to understand the clinical and social biomarkers to educate the community regarding better planning and 110 management of the disease. Various published studies have helped build models based on 111 identifying risk factors to predict severity and mortality and assist the hospitals in better 112 preparing for the COVID-19 surge. Thus, the proposed study intended to review the 113 114 medical records of deceased COVID-19 patients in our medical center to understand the disease progression during their respective hospital courses. The analysis of various 115 variables, including demographics, medical comorbidities, clinical data, medical 116 treatments, and their effects on each other, is expected to elucidate the COVID-19 disease. 117 predict severity and understand the mortality trend. It is critical to conduct such a study 118 119 especially in the remote setting hospital, to obtain the pattern despite complex patient heterogeneity. For example, as per (Supplementary Table S1), patient #24 is an 120 121 unvaccinated female in 70s with a history of hypertension, was found to be hypoxemic at 89%, requiring 15 lpm of supplemental O2. She had severe COVID-19 with imaging 122 findings consistent with bilateral infiltrates, laboratory values confirming lymphopenia, 123 elevated LDH, and D-dimer requiring prolonged ICU course and mechanical ventilation. 124 She was treated with remdesivir, steroids, paralytics, and antibiotics for bacterial 125 pneumonia. Her course was complicated with pulmonary embolism, ARDS and renal 126 dysfunction. She underwent tracheostomy but eventually was transitioned to comfort care. 127 Another patient #35 is a female in mid 60s with a history of a liver transplant, obesity, 128 hypertension, diabetes mellitus, chronic kidney disease who presented with SpO2 of 82% 129 on room air. She had a prolonged length of stay complicated with mechanical ventilation, 130 ARDS, pulmonary embolism, shock, and fungal pneumonia, eventually transitioned to 131 comfort care. She was appropriately treated with steroids, remdesivir, anticoagulation, 132 antibiotics, proning, paralytics, and antifungals. Her imaging showed moderate bilateral 133 infiltrates, and labs revealed elevated LDH and lymphopenia. The above examples of 134

unvaccinated and vaccinated patients (one each) show the complexity in the patient 135 presented in terms of their comorbidities and age. It is essential to associate the vaccination 136 status with other parameters to identify the predictors of mortality that can explain the 137 vaccination as a multivariate model. For example, closely looking into our cohort, 138 including the above two patients, obesity reveals as one of the critical comorbidities in 139 COVID 19 patients. This has also been reported in many other studies, including a CDC 140 141 report which suggests that approximately 40% of US adults are obese. Similarly, some demographic data have suggested that the risk of severity, intensive care admission, and 142 mortality increases with higher BMI⁹. Seeing this pattern, we identified inflammation 143 markers (detailed discussion in the results section) as critical predictors of mortality more 144 precisely in the unvaccinated group. One such critical marker is D-dimer, one of the 145 fragments produced during the degradation of blood clots and is known to be elevated in 146 patients with moderate to severe COVID-19. The elevation of D-dimer values correlates 147 with disease severity and is attributed to be a prognostic marker for inpatient mortality⁶. 148 Similarly, another clinical marker that can be critical predicting poor outcomes is 149 lymphopenia. It is associated with severe COVID-19 pneumonia and higher mortality. The 150 mechanism of lymphopenia in COVID-19 pneumonia remains obscured. There are 151 hypotheses such as lymphocyte sequestration in lungs, gastrointestinal tract, and lymphoid 152 tissues versus ACE receptors on lymphocytes being a direct target of SARS-CoV-2 versus 153 Cytokine storm further reducing the lymphocyte count $^{7-10}$. 154

Despite the plethora of research another critical aspect that remains warranted and requires more accumulation of clinical findings is the need for supplemental oxygenation in COVID-19 patients; higher the need for supplemental oxygen, the higher the risk for severe COVID-19 and death. This will guide the initial placement of the patient appropriately among intensive care unit, step down unit/progressive care unit, medical floors and monitor them closely for decompensation¹⁰.

Looking through the clinical and observational parameters in deceased unvaccinated and 161 vaccinated COVID-19 patients, it appears that point several common factors point toward 162 the worst outcomes. These subgroups of patients presented with hypoxemia on arrival had 163 elevated inflammatory markers, lymphopenia, bilateral lung involvement, required 164 mechanical ventilation, and had a prolonged hospital stay. These patients often developed 165 complications such as ARDS, multi-organ dysfunction, superimposed infections, 166 167 pulmonary embolism, pneumothorax, and pneumomediastinum during their hospital stay, eventually leading to the same outcome of death. 168

169 One concluding factor that can have both logistic and clinical impact in remote settings, hospitals, and low-income areas is the length of stay (LOS). Various serological studies 170 (including our cohort) suggested that severe COVID-19 patients develop acute respiratory 171 distress and multi-system organ failure and are associated with poor prognosis and higher 172 mortality. They have associated the severity with the length of ICU stay and hospitalization 173 ^{11–13}. For instance, Li et al ¹⁴ suggested that based on severity defined through inflammatory 174 markers, the length of hospitalization stay was ten days (IQR median) in all the patients, 175 12.5 days in severe disease (including critically ill), nine days in mild to moderate disease. 176 177 This is also reciprocated in our cohort, where the length of hospitalization is 11.0 days in the vaccinated group and 13.5 days in the unvaccinated group. Thus, the correlation of LOS 178 with other critical markers will barter as a prognostic evaluation model for critically ill 179 patients in remote settings. 180

The above mentioned explains the prognostic and clinical presentation of these biomarkers.
To summarize, our retrospective analysis aims to provide a bird' eye view of uniqueness
and possible disparity, if any, in a rural community-based hospital. The outcomes may help
the medical community in rural areas assess, stratify, and closely observe high-risk patients
and prevent untimely death.

186 Materials and Methods:

187 Statistical Analysis Plan

The primary model will be a logistic regression with the outcome variable being the 188 composite endpoint of severe COVID-19. Multiple imputations will be performed on 189 missing variables. For the secondary analysis of mortality, logistic regression based on 30-190 day mortality will be served. The goodness of fit of the models will be assessed by Harrell's 191 C-statistic with a 95% confidence interval determined by the method of DeLong. Variance 192 193 inflation factors will be computed for every predictor in the model. We plan to conduct sensitivity analyses restricting the primary research to patients with primary composite 194 endpoint, omitting one component of the severe COVID-19 composite endpoint (severe 195 illness requiring hospitalization). The exact process for the preceding model will be 196 197 conducted for the sensitivity analyses. All analyses will be performed using R v3.6.3, packages "rms", "Hmisc", "rpart", and "train." 198

199 Data Collection:

All of the variables requested for this analysis are either directly coded by the medical records group at Mercy Medical Center, Roseburg, or further investigators derived variables utilized in the course of analysis. Thus, obtaining the information necessary to complete this proposal should be feasible; however, due to hospital data guidelines, the data will only be available upon request after signing the Data Transfer Agreement (DTA).

Regarding the modeling exercise, the size of the cohort and rates of outcomes allowed us to complete the analysis as proposed. As of August 31, 2021, there were 38 patients with confirmed vaccination status, 5 of whom met the composite endpoint of severe COVID-19 in the vaccinated group. The model for our primary analysis involves a total of 36 degrees of freedom: age (1), sex (1), lab data performance status category (2, ordinal variable with 3 levels: 0, 1, 2 or greater), smoking status (1, binary variable, current/former or never), state of disease (2, a categorical variable with 3 levels: date of the first admission,....), line

of therapy received (2, categorical variable with 3 categories: untreated, first line, second
line), phase of therapy (2, categorical variable with three categories: induction,
consolidation, maintenance), and recent receipt of cytotoxic therapy (1, binary variable).
Therefore, the number of events is sufficient to power this analysis, assuming 26 events
per degree of freedom. Additional patient characteristics are demonstrated in Table 1 and
Table 2.

218 Sensitivity analyses

Analyses were performed in R version 4.0.3 (R Foundation for Statistical Computing,
Vienna, Austria), including the Hmisc, rms, ordinalNet, UpSetR, mice, extension
packages.

222 Missing data Imputation:

223 As shown in (Supplementary Table S1), we had missing values for several clinical variables such as D-Dimer (0-0.52 ng/l), Lymphocyte count (%), etc. Given the small 224 sample size of the study, we have an imputation algorithm to predict the missing values; 225 we have used the R package "mice" and "VIM" to visualize and predict the missing values. 226 We have used the k-NN algorithm with k=6 (Square root of the total number of patients) 227 to determine accuracy. We have identified only two patients with different predicted values 228 of D-dimer and Lymphocyte count. We have used values predicted through "mice" as final 229 230 values for the classification to identify the predictors of mortality. We have used m=5, maxit=50, meth='pmm', seed=500 to calculate the missing value in mice function. As 231 shown in (Figure S2(a)), we have missing values in several variables, and (Figure S2(b)) 232 shows post imputation; we didn't have any variables. The list of complete data is listed in 233 (Supplementary Table S2). 234

235 **Power calculation**

- The sample size of 38 patients (32 Vaccinated, 5 Unvaccinated, 1 Unknown) accrued as of
- August 2021 yields 80% power at an alpha of 0.05 to detect a hazard ratio of 0.01 for severe
- 238 COVID-19, assuming two unequally matched groups.

239 Classification and Predictors of mortality

Vaccinated, unvaccinated, and undetermined groups were used to build a model and identify the variables critical to the non-vaccinated group. We used "caTools" and "randomForest" R package to classify and preprocess the data. Our model was trained using 75 % of the patients and tested using 25%. To split the data, we used the caTools split function. We have used mtry=6 and No of tress= 501 to train the model. Gini Score has been used to determine the 15 top variables.

246 Logistic Regression

Using the R packages "epitools" and "gtsummary," **Table 1**, **Table 2**, and **Table S1** are generated to show patient demographics and a logistic regression equation to evaluate the variables contributing to mortality assess unvaccinated patients.

250 Charlson Comorbidity Index (CCI)

251 We calculated the Charlson Comorbidity Index (CCI) with the following assumptions, firstly for age < 50 we assigned score of 0, age >= 50 (1), age $< 60 \sim 1$, age $< 70 \sim 2$, age 252 $< 80 \sim 3$, age $>= 80 \sim 4$. Similarly, for autoimmune, obesity, CHF, HTN, ASCVD, COPD, 253 asthma, ILD, OSA, the availability of events was scored "1" else "0". For CKD, past 254 cancer, transplant availability of event was score "2" else "0". Further, for Active cancer 255 availability of event was scored "6" else "0", followed by DM where availability of event 256 was scored "3" else "0". We used the r package "comorbidity" to calculate CCI and 257 "ggplot2" to plot CCI. 258

259 **Results**

In the context of remote hospitals, patients and potential outcomes were distributed in a 260 manner that led to some of the most critical outcomes for COVID 19. The patient 261 characteristics are outlined in (Figure 2). Table 2 depicts the distribution of patients in our 262 medical center. (Figure 2) illustrates how we categorized 71 collected clinical 263 observations and potential biomarkers across eight broad categories. As indicated by 264 (Figure 2), one of the strengths of our data is the prevalence of heterogeneity, such as 265 marital status*, BMI, and smoking status*. Furthermore, as stated earlier, most of our 266 patients are not vaccinated. Numerous studies have suggested that lifestyle and social 267 factors (marital status, smoking)* impact outcomes ¹⁵¹⁶. Similarly, smoking and passive 268 smoking during the lockdown also negatively impacted children, as well as adults and 269 family members¹⁷. We had 15 former and two current smokers in our cohort and 23 patients 270 with higher BMIs (>30). In COVID-19 patients¹⁸ both factors have been associated with 271 the worst outcome. Additionally, chronic diseases such as cancer, autoimmune diseases, 272 cardiovascular disorders, asthma, and hypertension contribute towards the worst outcome 273 in COVID 19 infected patients who were unvaccinated¹⁹. Also, the cohort is sufficiently 274 extensive to explain the associated complications that may be causing the worst outcome 275 in COVID 19 unvaccinated patients. According to Figure 2, we have collected laboratory 276 findings such as CRP, D-Dimer, Lymphocyte, CT-based severity, SpO2 on arrival, 277 treatments, and complications. The selection will allow us to explain the role of biomarkers 278 converges to predictors of mortality and aid the treating physician in opting for further 279 treatment. In light of the factors presented in (Figure 2), the following are significant 280 conclusions we derived from the current study. 281

* Smoking status, Marital status, Age, Race, Ethnicity, Gender, Weight, Height is subject to IRB approval and available for peer review only.
 The * sign only denoted at the first occurrence of variable, however, the data availability conditions remain the same for earlier mentioned
 variables.

286 **Patient Distribution:**

Our cohort consisted of 38 records. There were no exclusion criteria applied, resulting in 287 288 38 records being included in the primary analysis (Supplement Table 1). The median age of the included cohort was 75.5 years (interquartile range: 44 to 95 years) *, and the 289 majority, 57.89% (n=22), were male, and 42.1 % (n=16) were female*. Non-Hispanic 290 whites accounted for half the cohort, while non-Hispanic blacks* accounted for 2.63% 291 (n=1). 81.57% (n=31) of the patients were without any vaccinations. These are similar 292 proportions to the patients without vaccination, 10.52% (n=4) were treated within first 293 three months, and 89.47% (n=34) were not treated within first three months of data 294 295 collection. Over 47.36% (n=18) of the cohort had severe bilateral lung involvement based on imaging, and over 52.63% (n=20) required mechanical ventilation. 92.1% (n=35) 296 received remdesivir; 94.73% (n=37) received steroids and 13.15% (n=5) received 297 tocilizumab. A total of 81.57% (n=31) of the patients were unvaccinated. Tables 1 and 2 298 provide additional information regarding the patient. 299

300 Patient outcomes

The data collected over the span of two weeks from a remote hospital setting led to critical observations. We calculated interquartile range (IQR) median values for the variables. Thus, all discussion further will be IQR median. As demonstrated in **(Table 1)** in 38 patients, the median age is 76. It is essential to note that our population of patients is distributed as follows: Unvaccinated: 31 (82%), Unknown and Vaccinated are 2 (5.3%) and 5 (13%), respectively. We further looked into some of the critical COVID 19 associated variables in the non-vaccinated group to compare all-cause mortality among

severe COVID 19 patients treated at Mercy Medical Center, Roseburg, Oregon. There have 308 been various criteria to define the severity of illness; however, as discussed in recently ^{20–} 309 ²³ published articles following clinical parameters have higher predictive value in 310 hospitalized and unvaccinated COVID 19 patients. a) Respiratory distress, Respiratory 311 rate > 30/min b) Mean O2 saturation $\leq 93\%$ in the resting state c) partial pressure of oxygen 312 in arterial blood (PaO2)/oxygen concentration (FiO2) ≤300 mmHg d) lung involvement on 313 imaging >50% within 24–48 h e) The critical value of initial D-Dimer, peak D-Dimer, 314 initial NLR (neutrophil to lymphocyte ratio) and peak NLR in prognosticating of intubation 315 was 0.73 mg/L, 12.75 mg/L,7.28 and 27.55 f) lymphocytopenia g) duration of admission 316

317 post-infection.

318 *Lymphocyte count and D-Dimer in conjunction with other clinical characteristics may* 319 *influence the outcome of unvaccinated COVID 19 patients in remote areas*

Earlier, we talked about how the more extensive cohort study analysis can facilitate the 320 potential biomarkers for the worst outcome in COVID 19. Figure 1 illustrates how BMI, 321 vaccination status, and gender are distributed and suggests that age, gender, and body mass 322 index (BMI) may impact the immune response to vaccines²⁴. Furthermore, the 323 epidemiological studies within the state of Oregon demonstrate that 30% of the adults in 324 Douglas County are obese, which is significantly higher than the state average of 27%, 325 despite the county having an average age of 38.7 years²⁵. According to the County Vaccine 326 Tracker, as of 19th November 2021, the vaccination rate stands at 55.3%, and the risk level 327 is extremely high. To account for this, we examined our cohort's age, gender, BMI, and 328 vaccination status (Figure 1). As shown in (Figure 1), BMI is relatively higher in 329 unvaccinated male patients. For the sake of simplicity in the study, we avoided conclusions 330 for the unknown vaccinated group due to their singleton number. The male gender was also 331 associated with higher mortality in earlier studies²⁶. Therefore, we can correlate our 332

indicators and predictors of mortality with larger-scale studies despite the small cohort size. 333 Once we established the social parameters in the earlier section and their role in the 334 outcome, we also looked into all the clinical variables to identify the predictors of mortality 335 to differentiate the vaccinated and unvaccinated patient groups. As discussed and explained 336 in the methods, we used binary classification (vaccinated, unvaccinated) using Random 337 Forest (RF) machine learning method to classify the groups. Further, we used Gini Score to 338 339 rank the clinical variables. The ranked list (Top 15) of clinical variables that differentiate 340 groups in all patients with the worst outcome is depicted in Figure 3(a).

Further, due to our small sample size, we also looked into the conservative approach of 341 identifying the correlation between different variables and extracting the significant 342 343 variables that may have contributed to mortality Figure 3(c and b). As demonstrated in Figure 3 (a), SpO2 (on arrival), CRP level, lymphocyte count, BMI and associated 344 markers (age, weight), length of hospitalization, D-dimer, and paO2 (mm/hg) are expected 345 to be predictors of mortality in unvaccinated patients. For a closer look at these variables, 346 the correlation plot illustrates the correlation between them. As shown in Figure 3 (b), age, 347 BMI, and lymphocyte count have a negative correlation of outcome, and it has been 348 established that lymphocyte count, B cells, NK cells, cytotoxic and helper T cells are 349 reduced in severe COVID 19 patients²⁷. 350

The severity signifies the inverse relationship and elucidates the severity of SARS-COV2 351 in our cohort. Further, weight (kilograms), BMI, and CRP levels also negatively correlate 352 with the outcome for the number of visits prior to final admission. As shown in Figure 3 353 (a), these markers are elucidated as critical predictors of mortality, and a higher number of 354 visits prior to admission can correlate with delay in treatment and response. Studies have 355 shown that weight (kilograms), BMI, and CRP levels are predictors of mortality in severe 356 COVID 19 cases. It has been documented that severe COVID 19 is associated with higher 357 inflammatory mediators due to cytokine storms. These markers may allow early 358

identification or even prediction of disease progression and define admission priority^{28.} 359 CRP is also known as an active regulator for innate immunity and predictor for mechanical 360 ventilation. According to the positive correlation between CRP and D-dimer values, both 361 of these values are likely to be elevated during the early stages of COVID 19 infection due 362 to systemic inflammation^{29,30}. Both these values have a proportional relationship with the 363 severity of the disease. As discussed earlier, similar to CRP, elevated D-dimer at the time 364 365 of admission could be an indicator of severe COVID 19 infection requiring ICU admission³¹ as shown in Figure S3 (b). All our patients had elevated D-dimer during 366 treatment compared to the vaccinated group (actual and predicted) displayed in Figure 367 2 and Table 1. Further, D-dimer levels on hospital admission have been identified as being 368 associated with increased mortality, and a positive correlation of CRP and D-dimer is also 369 associated with cardiac arrest and coronary heart disease. As we can see in Figure 370 2, Table 1, and Table 2, we had a higher number of unvaccinated patients with a high 371 prevalence of cardiac arrest. 372

The elevation of CRP and D-dimer also increases the probability of complications such as 373 pulmonary embolism, acute respiratory distress syndrome (ARDS), and superimposed 374 bacterial pneumonia³². (Figure 2) and Table 2, indicates that many unvaccinated patients 375 from our small cohort had these complications. Hence, it is established that endothelial 376 damage caused by inflammation leads to increased severity of COVID 19 in our patient 377 cohort. The systemic understanding and function are discussed below in the discussion 378 section. However, even with the remote setting, the systemic track of CRP level, D-dimer, 379 and lymphocyte count can allow the physician to plan for early hospitalization and 380 mechanical ventilation. The overall association of correlations among a few clinical 381 variables that may not be statistically significant due to the small sample size is also 382 383 depicted in Figure 3 (C). As such, in Figure 3(B), SpO2 (on arrival) has a strong negative correlation of outcome with the number of visits prior to final admission and length of 384

hospitalization (days). Precisely, oxygen saturation (SpO2) values of less than 90% on 385 admission have been identified as the predictor of mortality in COVID 19 patients. Another 386 strong correlation was seen between PaO2/FiO2 & SpO2/FiO2. Even though not evident 387 based on the correlation plot as shown in Figure 3(a), both are critical variables to 388 differentiate vaccinated and unvaccinated groups in our machine learning model. The 389 significance proves that PaO2/FiO2 is a strong predictor of mortality, as shown in Figure 390 3(c). Even though values are not statically significant, PaO2 and SpO2 positively correlate 391 with the number of visits prior to final admission. We did not see any solid indicators for 392 the length of hospitalization, SpO2, and PaO2 despite being critical predictors of mortality 393 in COVID 19 patients³³. However, these two factors can be one of the mediatory factors in 394 the putative connection between the length of hospitalization, number of visits prior to final 395 396 admission. Hence, we elucidate that despite limited resources, many such studies can be conducted in remote centers to understand the location-agnostic prognostic tool of COVID 397 19 management and treatment, such as hospitalization based on vaccination status and 398 other treatment options. 399

400 *Age and other metabolic features contributed highly to mortality along with* 401 *inflammatory markers*

We calculated the Charlson Comorbidity Index (CCI)³⁴ to identify the pattern of mortality 402 and contributing factors that may be causing the higher levels of inflammation. According 403 404 to (Figure S5), the distribution of CCI across all comorbidities in our cohort clearly illustrates that most patients fall into the high-risk group with higher age, BMI, and obesity. 405 Additionally, hypertension and diabetes are prevalent, indicates that metabolic pathways 406 played a significant role in mortality. Numerous studies have suggested that patients with 407 COVID 19 have higher levels of cytokine storms due to cardiometabolic disease^{35 36}. The 408 Centers for Disease Control and Prevention (CDC) contends that Douglas county is at 409 greater risk for COVID 19 due to its average age, diabetes, and high body mass index 410

(BMI). Additionally, we examined individual CCI for each patient, as shown in (Figure 411 S6). Keeping the CCI score zero as a baseline, it is evident that any score in the range of 412 three is prognostically indicative of death or poor outcome in COVID 19 patients. An 413 increase of one point above this will result in an increase of 16% in mortality. (Figure s6) 414 depicts that most of our patients had CCI > 3, which indicates that most of these patients 415 were considered high risk. M2 and M16 with higher CCI were unvaccinated, while M36 416 with the lowest CCI was vaccinated. Even the lowest CCI patient was >3, meaning that 417 418 this patient was in a higher-risk group with obvious signs on imaging and hypoxemia on presentation (SpO2 of 80% on room air). 419

420 **Discussion**

COVID 19 poses unique risks to patients without vaccination. This study examined the 421 characteristics and clinical outcomes of a small cohort of COVID 19 unvaccinated and 422 423 vaccinated patients in a remote hospital in Roseburg, OR, USA. Unvaccinated Non-Hispanic/White-male patients represented the majority of all COVID 19 positive patients 424 who could not survive post-treatment or hospitalization. Patients had a higher prevalence 425 of obesity, hypertension, diabetes at baseline. A higher percentage of unvaccinated patients 426 presented with elevated inflammatory markers levels than unknown and vaccinated 427 patients. Most of the patients who received critical care or mechanical ventilation were 428 unvaccinated and obese. The white race, higher median age, a higher score on the Charlson 429 430 Comorbidity Index, public insurance (Medicare or Medicaid), resident in a low-income 431 area, remote location of the hospital, limited healthcare resources, higher inflammatory markers, and obesity were associated with increased odds of hospital admission (Table 2). 432 Whites (Male) were overrepresented among all patients who died in the hospital (78.6%). 433 The current trends in Douglas county¹ being catalogued as a high-risk zone insinuate that 434 lower vaccination rates and comorbidities prevalent in the area are expected to be the 435 prognostic predictors of mortality. The remote settings also have their challenges (see next 436

437 section) and other social influences indicated by CDC, such as a higher rate of vaccine 438 hesitancy and dependence on public insurance. This outcome is in line with earlier 439 published studies with similar results^{37,38}. Hypoxemic respiratory failure, acute respiratory 440 distress syndrome, superimposed pneumonia, renal dysfunction, and shock were the most 441 commonly identified complications during hospitalization. Relevant laboratory 442 abnormalities included lymphopenia, elevated levels of D-dimer, and other markers of 443 inflammation.

As described in the results Figure 3(b), CRP, D-dimer, lymphocyte count, BMI, and
PaO2/FiO2 ratio are the key predictors of hospitalization and mortality. In addition, our
results revealed that respiratory deterioration-associated biomarkers (PaO2/FiO2 and SpO2
on arrival) have a higher predictive capability of mortality.

We have conducted a single-center and remotely located hospital's retrospective cohort 448 449 analysis of deceased COVID 19 patients. We started teasing out the data from an observational perspective, as displayed in (Table 1). We have used median (IQR) to 450 generate all the summaries and confidence intervals during analysis³⁹⁴⁰. A higher wait time 451 for care among low-income patients may also result from the severity of their clinical 452 presentation with multiple ER/urgent care visits before hospitalization. Several factors may 453 contribute towards the occurrence of COVID 19 in our study population, including 454 remoteness, disparities in vaccination coverage, and other factors, suggesting that death in 455 456 our population are likely multifactorial. In addition, the lower-income level, hesitation regarding vaccinations, and lack of access to upgraded medical facilities may have 457 adversely affected their admission time. 458

According to the Oregon State Public Health Department², Douglas county hospitals are still stretched thin in providing care to COVID 19 patients; most are unvaccinated. In addition, the hospital continuously faced staff and bed shortages causing the grinning

462 effect. The report also indicated that obesity, diabetes, and hypertension were more463 prevalent in low-income and lower education counties, irrespective of race.

464 Our cohort found that elevated levels of CRP and D-dimer correlated with disease severity. 465 It is established that COVID 19 is associated with a high incidence of thrombotic 466 complications due to the unique interplay between the SARS-COV2 virus and endothelial 467 cells. The D-dimer molecule is a product of the degradation of the fibrin protein after lysis 468 by the thrombin, plasmin, and factor XIIIa enzymes. This method can also be used in 469 clinical evaluation to identify ongoing coagulation. A higher CRP level induces endothelial 470 dysfunction as well.

This study confirms previously described clinical presentations, laboratory findings, and 471 outcomes of COVID 19-related hospital admissions. The observed differences in the 472 clinical presentation may also reflect differences in underlying chronic conditions on 473 474 hospital presentation. To explain the relationship of the clinical presentation, we had a nonparametric correlation analysis (Figure S3(c)), the positive correlation between the 475 number of days on mechanical ventilation, the number of days in ICU, and the length of 476 hospitalization are unique to our cohort. Symptoms onset prior to arrival and positive tests 477 to hospitalization also have a positive correlation. Our findings suggest that more studies 478 are warranted to assess the response of inflammatory markers in response to this novel 479 coronavirus with respect to low-income status, distance from medical centers, and 480 481 vaccination status. These and other unrevealed factors may influence the difference in the rate of hospitalization, the timing of patients' admission, the rate of increasing hospital's 482 483 capacity, and the overall outcome.

This study mirrored the findings of similarly conducted studies that showed associations between the risk of in-hospital death, demographic factors (age, BMI), clinical factors (Ddimer, CRP) as well as other biomarkers (as per **Figure 1(a)**). For example, in a metaanalysis of Deng et al., ⁴¹ Lodigiani et al.³⁰ suggested that the lowest to the highest increase
in D-dimer was more strongly associated with death than patients with lower D-dimer at
baseline. In addition, a positive correlation was found between CRP levels and the need for
supplemental oxygenation and invasive ventilation. This pattern was also evident in our
small cohort. It has been suggested in a number of studies, including Hu et al. ⁶, and Srikant
et al. ⁴² that CRP, D-dimer, and lymphocyte count can be used as prognostic markers of
disease severity for COVID 19 patients.

Despite the limited sample size, difficulties in obtaining data, remote infrastructure, and 494 missing data, our statistically valid methods permitted us to conclude that D-Dimer and 495 CRP are prognostic biomarkers in any setting and correlate with the need for mechanical 496 ventilation is excellent. Moreover, this information has also concluded that inflammation-497 induced cytokine storm is associated with coagulopathy in COVID 19 infected patients. 498 Early rise in D-dimer suggests that coagulopathy acts as a prodrome of cytokine 499 Nonetheless, it was challenging to see any direct effects of treatment, we followed the 500 standard treatment protocols as described in a variety of exciting articles⁴³, and our 501 observations can be seen in (Figure S4). In terms of treatment, the mean hospital stay was 502 11.4 (M) and 9.8 (F) days, respectively. Most commonly prescribed medications were 503 dexamethasone (n=37), remdesivir (n=35), enoxaparin/UFH (n=35) and tocilizumab (n=5). 504 As indicated in (Figure S4), 20 patients required mechanical ventilation, 27 required non-505 invasive ventilation, and 26 required high-flow oxygen through nasal cannulas. According 506 to our data in Table 1 and Table 2, most of our patients had complex comorbidities (Figure 507 S5), with medications and interventions showing minimal impacts. Many studies have 508 reported that low-risk patients with mild COVID 19 infection, stratified based on D-Dimer 509 and CRP levels, can be managed symptomatically without any specific drug intervention. 510 511 Consequently, these markers can also monitor progression in extremely critical care patients. Thus, our biomarkers can also be utilized by the community to a) determine an 512

individual's i) develop a treatment plan, (ii) determine the need for hospitalization, and (iii)
eligibility for mechanical ventilation.

Although this study was able to identify critical biomarkers for severe COVID 19 patients, 515 it also has some limitations. This being a retrospective analysis, the findings are primarily 516 used in generating hypotheses, not necessarily in clinical practice. Furthermore, as a 517 registry analysis, there is an inherent bias in the patient selection determined by registry 518 519 entrant decided based on pre-defined criteria such as outcome in our case. Consequently, the study population likely has a higher COVID 19 severity than the general population of 520 cancer patients with COVID 19. Additionally, as discussed above, this study included a 521 more significant proportion of unvaccinated patients than other analyses, and this may have 522 led to improved generalizability reflecting the impact of COVID 19 in remote settings. 523 However, to maximize sample size, a small number of vaccinated patients were added to 524 the cohort, limiting the generalizability of the findings. Additionally, there are significant 525 differences between the timing of COVID 19 diagnosis in this study and the epidemiology 526 of the pandemic in the general population, with an overrepresentation of diagnoses in the 527 early part of the pandemic period. In all likelihood, this study does not include patients 528 with delta-variant since it includes data up until the third trimester of 2021. In light of the 529 530 ordinal outcome of COVID 19 severity, including metrics such as hospitalization and ICU admission, patients without vaccination may have an advantage in being admitted to higher 531 levels of care instead of their intrinsic clinical presentation. 532

It was observed in our study cohort, patients with severe hypoxemic respiratory failure reported increased length of stay prior to the need for mechanical ventilation. While this may not explain all the parameters linked to increased COVID 19 severity, it may contribute to some findings. Furthermore, our study is the largest to date for unvaccinated patients in remote settings and uses machine learning to demonstrate that inflammation affects COVID 19 severity, the sample size was insufficient to determine the independent

effects of specific treatments. Future efforts should be aimed at performing such analyses.
Unfortunately, some laboratory investigations were not conducted on all patients. The role
of these factors in the clinical presentation of the study population may not have been
sufficiently considered.

Based on the results of this analysis, it is concluded that patients without vaccination in remote settings have a relatively increased risk of developing severe COVID 19. This risk is further increased in conjunction with other clinical factors. It is essential to consider the individual patient scenario in the context of community infectivity, hospital resources, patient's baseline characteristics, and disease response with prognosis. The health care needs of this population remain high, and they require improved primary prevention with therapeutic strategies.

550 Notwithstanding these limitations, this study provides comparative epidemiological 551 characteristics of unvaccinated patients in remote setting hospitals who are 552 underrepresented in the COVID 19 medical literature to date. The study is also intended to 553 shed light on differences in clinical presentation in such remote hospital settings.

554 Limitations in remote setting hospital for health care delivery

In the wake of COVID 19, healthcare workers felt the brunt of it. Often this impact is 555 multidimensional, encompassing factors like work management, mental health, and social 556 557 needs. Another factor contributing to the prevalence of these issues is the disparity between medical centers in urban and rural areas. For example, the pandemic had twice the mortality 558 rate in remote centers than in urban centers⁴⁴. In addition, a large number of rural centers 559 were dealing with shortages of physicians and limited access to vital lifesaving equipment, 560 including non-invasive ventilators, ventilators, dialysis machines, and medications that are 561 required in large quantities to treat moderate to severe COVID 19 infections. 562

One more Gordian knot was the scarcity of nurses, respiratory therapists, and medical 563 residents necessary to ensure adequate coverage within the already overwhelmed intensive 564 care units (ICUs) and uninterrupted overflow into the COVID units. Through this uniquely 565 positioned scenario, some of the most pressing issues during the pandemic were 566 highlighted, and respondents were asked to display resilience during overworking 567 conditions worsening their physical and mental turmoil. In part due to hospitals having an 568 uneven distribution of resources, transportation of patients needing higher levels of care, 569 such as the trial of extracorporeal membrane oxygenation (ECMO), was further hampered 570 and prolonged. Moreover, tertiary centers participated in the COVID 19 experimental 571 treatments in a rapidly evolving protocol environment. As a result, several new medications 572 were made available, and FDA compassionate release was granted for their patients. On 573 the other hand, the remote hospitals had limited access to resources and were more 574 vulnerable. Among such scenarios is outpatient monoclonal antibody treatment availability 575 in rural settings with limited infrastructure to potentially reduce the severity of the COVID 576 19 infection set up late in the pandemic. 577

Even with these obstacles, the hospital administration endeavors to provide up-to-date health care for their community members. In addition, the advent of telemedicine has enabled urban and rural areas to stay closely connected during this pandemic period. However, the fact remains that many possibilities remain unexplored and yet to be implemented to continue catering quality medical care throughout the country.

583 Imputation Impact:

584 We imputed clinical variables with a K-NN algorithm to fix the missing data issue; 585 although theoretically, it was more sensitive and specific, the actual values could be 586 different based on clinical representation, treatment, and other prognostic variables.

588 Figure Legends

Figure 1: The overall distribution of patients according to their vaccination status. Basedon age distribution and BMI, Pearson's correlation was calculated.

Figure 2: The flow chart indicates all the clinical variables collected and their distribution
based on demography, treatment, complications, laboratory findings, and end of life
distribution.

Figure 3: (a) Shows top 15 clinical variables based on random forest classification Gini score. (b) indicated the correlation between the top 15 clinical variables. The cross shows the non-significance based on p-value < 0.01. (c) defines the correlation among the top 15 clinical variables without indicating p-value significance. It shows that the correlation and p-value can be omitted due to the non-heterogeneous small sample size.

Table 1: The clinical characteristics of the COVID-19 patients during the 20-month period,based on the mean (IQR)

Table 2: The clinical characteristics of the COVID-19 patients were stratified by vaccination status (vaccinated, unvaccinated, and unknown) over the 20 months, based on the mean (IQR). The Kruskal-Wallis rank-sum test determined the significance of distribution, Fisher's exact test.

605

606

607

608

610 Supplementary File Details

- **Figure S1:** Distribution of patients based on age, height, weight, and BMI.
- **Figure S2:** Missing values in clinical variables and imputation of missing values.

Figure S3: (a)Distribution of patients for vaccination status for Length of stay, patient's RT PCR position day and hospitalization, and the total number of visits prior to hospitalization (b)Distribution of patients for vaccination status for inflammatory markers such as D-Dimer, CRP, lymphocyte and SpO2, and paO2. (c) The Pearson's correlation of all the clinical variables in the study, the significance can be determined based on P-value

618 <0.05.

Figure S4: Treatment and interventions for all the patients in the cohort distributed basedon medications and interventions.

Figure S5: The Charlson Comorbidity Index (CCI) distribution for each comorbidity forall the patients.

623 Figure S6: Each patient's Charlson Comorbidity Index (CCI) distribution.

624 **Table S1:** Logistic regression to classify the vaccination status.

625 Declaration of interests

Any of the authors declare no conflict of interest. The authors have no financial interestsrelated to the study.

628 Data Sharing

629 The data can be retrieved using the guidelines set forth by Mercy medical center.

631 Contributions

NJ designed the scientific questions, formed the IRB, implemented the clinical
conceptualization, identified vital datasets, and contributed to manuscript preparation. KP
conceptualized, organized, and contributed to manuscript preparation and analyses results.
RS, GK, and AA helped with data collection and manuscript review. Finally, AJ wrote the
manuscript and helped analyze the data.

637 Acknowledgments

638 The authors are profoundly grateful for dedicating this research to all the patients and their families unfailingly; their generosity and kindness allowed the existence of this 639 study. In addition, the authors would like to thank Jenny Kaylor (Quality Analyst at 640 MMC) for their help with data collection from CHI Mercy Health, Roseburg. Lastly, the 641 authors are eternally thankful to all the healthcare and support staff involved in patient 642 care at CHI Mercy Health, Roseburg, Oregon. 643 644 645 646 References 647 648 1. Mileham, K. F. et al. Changes Over Time in COVID-19 Severity and Mortality 649 in Patients Undergoing Cancer Treatment in the United States: Initial Report 650 From the ASCO Registry. JCO Oncology Practice OP.21.00394 (2021) 651 doi:10.1200/OP.21.00394. 652 2. Xu, S. COVID-19 Vaccination and Non–COVID-19 Mortality Risk — Seven 653 654 Integrated Health Care Organizations, United States, December 14, 2020–July 31, 2021. MMWR Morb Mortal Wkly Rep 70, (2021). 655

- 656 3. Jin, Y. *et al.* Endothelial activation and dysfunction in COVID-19: from basic
- mechanisms to potential therapeutic approaches. *Sig Transduct Target Ther* 5,
 1–13 (2020).
- 4. Mallapaty, S. COVID vaccines cut the risk of transmitting Delta but not for
 long. *Nature* (2021) doi:10.1038/d41586-021-02689-y.
- 5. Gohil, S. K. & Huang, S. S. Community COVID-19 Incidence and Health Care
 Personnel COVID-19 Seroprevalence. *JAMA Network Open* 4, e211575 (2021).
- 663 6. Yao, Y. *et al.* D-dimer as a biomarker for disease severity and mortality in
- 664 COVID-19 patients: a case control study. *Journal of Intensive Care* **8**, 49 (2020).
- 665 7. Huang, I. & Pranata, R. Lymphopenia in severe coronavirus disease-2019
- (COVID-19): systematic review and meta-analysis. *Journal of Intensive Care* 8,
 36 (2020).
- 8. Lin, L., Lu, L., Cao, W. & Li, T. Hypothesis for potential pathogenesis of
- SARS-CoV-2 infection-a review of immune changes in patients with viral
 pneumonia. *Emerg Microbes Infect* 9, 727–732 (2020).
- 9. Xu, H. *et al.* High expression of ACE2 receptor of 2019-nCoV on the epithelial
 cells of oral mucosa. *Int J Oral Sci* 12, 1–5 (2020).
- Tan, L. *et al.* Lymphopenia predicts disease severity of COVID-19: a
 descriptive and predictive study. *Sig Transduct Target Ther* 5, 1–3 (2020).
- 11. Taleb, S. *et al.* Predictive Biomarkers of Intensive Care Unit and Mechanical
- 676 Ventilation Duration in Critically-Ill Coronavirus Disease 2019 Patients. *Front*
- 677 *Med (Lausanne)* **8**, 733657 (2021).
- Pascua, F. V. *et al.* A multi-mechanism approach reduces length of stay in
 the ICU for severe COVID-19 patients. *PLOS ONE* 16, e0245025 (2021).
- 680 13. Prognostic Value of Inflammatory Biomarkers in Patients with Severe
- 681 COVID-19: A Single-Center Retrospective Study Gönül Açıksarı, Mehmet
- 682 Koçak, Yasemin Çağ, Lütfiye Nilsun Altunal, Adem Atıcı, Fatma Betül Çelik,

- Furkan Bölen, Kurtuluş Açıksarı, Mustafa Çalışkan, 2021. https://journalssagepub-com.stanford.idm.oclc.org/doi/full/10.1177/11772719211027022.
- 14. Xue, G. *et al.* Novel serological biomarkers for inflammation in predicting
 disease severity in patients with COVID-19. *Int Immunopharmacol* 89, 107065
 (2020).
- 688 15. van Veenendaal, N. et al. Six-Month Outcomes in COVID-19 ICU Patients
- and Their Family Members: A Prospective Cohort Study. *Healthcare (Basel)* 9,
 865 (2021).
- 691 16. Gamberini, L. et al. Quality of life of COVID-19 critically ill survivors after
- 692 ICU discharge: 90 days follow-up. *Quality of Life Research* 1
- 693 doi:10.1007/s11136-021-02865-7.
- 694 17. Polverino, F. Cigarette Smoking and COVID-19: A Complex Interaction.
 695 Am J Respir Crit Care Med 202, 471–472 (2020).
- Rodgers, G. P. & Gibbons, G. H. Obesity and Hypertension in the Time of
 COVID-19. *JAMA* 324, 1163–1165 (2020).
- Sanyaolu, A. *et al.* Comorbidity and its Impact on Patients with COVID-19.
 SN Compr Clin Med 1–8 (2020) doi:10.1007/s42399-020-00363-4.
- 20. Lu, C. *et al.* Prognostic value of lymphocyte count in severe COVID-19
- patients with corticosteroid treatment. *Sig Transduct Target Ther* **6**, 1–3 (2021).
- 702 21. Thoreau, B. *et al.* D-Dimer Level and Neutrophils Count as Predictive and
- 703 Prognostic Factors of Pulmonary Embolism in Severe Non-ICU COVID-19
- 704 Patients. *Viruses* **13**, 758 (2021).
- Song, X. *et al.* Post-anticoagulant D-dimer is a highly prognostic biomarker
 of COVID-19 mortality. *ERJ Open Research* 7, (2021).
- 707 23. Berger, J. S. et al. Prevalence and Outcomes of D-Dimer Elevation in
- 708 Hospitalized Patients With COVID-19. Arteriosclerosis, Thrombosis, and
- 709 *Vascular Biology* **40**, 2539–2547 (2020).

710	24.	Pellini, R. et al. Initial observations on age, gender, BMI and hypertension in	
711	antibody responses to SARS-CoV-2 BNT162b2 vaccine. EClinicalMedicine 36,		
712	(2021).		
713	25.	Douglas County Health Department - Health Impact Assessments.	
714	https://www.douglascountyhealth.com/staying-healthy/health-impact-		
715	assessments.		
716	26.	Nguyen, N. T. et al. Male gender is a predictor of higher mortality in	
717	ho	spitalized adults with COVID-19. PLoS One 16, e0254066 (2021).	
718	27.	Löhr, P. et al. Impact of age and gender on lymphocyte subset counts in	
719	patients with COVID-19. Cytometry Part A n/a,.		
720	28.	Luan, Y., Yin, C. & Yao, Y. Update Advances on C-Reactive Protein in	
721	COVID-19 and Other Viral Infections. Frontiers in Immunology 12, 3153		
722	(2021).		
723	29.	Becher, Y., Goldman, L., Schacham, N., Gringauz, I. & Justo, D. D-dimer	
724	and C-reactive Protein Blood Levels Over Time Used to Predict Pulmonary		
725	Embolism in Two COVID-19 Patients. Eur J Case Rep Intern Med 7, 001725		
726	(2020).		
727	30.	Valerio, L. et al. Course of D-Dimer and C-Reactive Protein Levels in	
728	Su	rvivors and Nonsurvivors with COVID-19 Pneumonia: A Retrospective	
729	Aı	nalysis of 577 Patients. Thromb Haemost 121, 98-101 (2021).	
730	31.	Hashem, M. K. et al. Prognostic biomarkers in COVID-19 infection: value	
731	of anemia, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and D-		
732	di	mer. The Egyptian Journal of Bronchology 15, 29 (2021).	
733	32.	Fuchs-Buder, T. et al. Time course of procoagulant activity and D dimer in	
734	bronchoalveolar fluid of patients at risk for or with acute respiratory distress		
735	syndrome. Am J Respir Crit Care Med 153, 163–167 (1996).		
736	33.	Tobin, M. J., Jubran, A. & Laghi, F. PaO2/FIO2 ratio: the mismeasure of	

737 oxygenation in COVID-19. *European Respiratory Journal* 57, (2021).


- 738 34. The impact of charlson comorbidity index on mortality from SARS-CoV-2
- virus infection and A novel COVID-19 mortality index: CoLACD Varol 2021
- International Journal of Clinical Practice Wiley Online Library.
- 741 https://onlinelibrary.wiley.com/doi/full/10.1111/ijcp.13858?casa_token=l-
- 742 AgR1cUQl0AAAAA%3A5huIDWcIsMovFYCbdotI-
- 743 TRO7ZzSZ8rdHJ_tzCxySB6B1tmluQVybvzptvbeaCwA9rLXlBMHlpJE.
- 744 35. Hehar, J., Todter, E. & Lahiri, S. W. Association of Patient Characteristics,
- Diabetes, BMI, and Obesity With Severe COVID-19 in Metropolitan Detroit,
- 746 MI. *Clin Diabetes* cd210065 (2021) doi:10.2337/cd21-0065.
- 747 36. Dandona, P. & Ghanim, H. Diabetes, Obesity, COVID-19, Insulin, and
 748 Other Antidiabetes Drugs. *Diabetes Care* 44, 1929–1933 (2021).
- 749 37. Dyer, O. Covid-19: Unvaccinated face 11 times risk of death from delta
 750 variant, CDC data show. *BMJ* 374, n2282 (2021).
- 751 38. Agrawal, U. et al. COVID-19 hospital admissions and deaths after
- 752 BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2.57 million people in
- Scotland (EAVE II): a prospective cohort study. *The Lancet Respiratory*
- 754 *Medicine* **0**, (2021).
- 755 39. Leentjens, J., Haaps, T. F. van, Wessels, P. F., Schutgens, R. E. G. &
- 756 Middeldorp, S. COVID-19-associated coagulopathy and antithrombotic
- agents—lessons after 1 year. *The Lancet Haematology* **8**, e524–e533 (2021).
- 40. Hein, T. W. *et al.* Human C-reactive protein induces endothelial dysfunction
 and uncoupling of eNOS in vivo. *Atherosclerosis* 206, 61–68 (2009).
- 760 41. Zeng, F. *et al.* Association of inflammatory markers with the severity of
- 761 COVID-19: A meta-analysis. *Int J Infect Dis* **96**, 467–474 (2020).
- 762 42. Creel-Bulos, C. *et al.* Trends and diagnostic value of D-dimer levels in
- patients hospitalized with coronavirus disease 2019. *Medicine* 99, e23186

- 764 (2020).
- 43. Juul, S. et al. Interventions for treatment of COVID-19: a protocol for a
- ⁷⁶⁶living systematic review with network meta-analysis including individual patient
- 767 data (The LIVING Project). *Systematic Reviews* **9**, 108 (2020).
- 768 44. Huang, Q. et al. Urban-rural differences in COVID-19 exposures and
- outcomes in the South: A preliminary analysis of South Carolina. *PLOS ONE*
- **16**, e0246548 (2021).

- ...


- ----

791 Figure 1




793 Figure 2









- 797
- 798
- 799




(c)




801




(c)




804 805





811 Figure S4



816